OS Therapies Inc.: Promising OST-HER2 Developments and Strategic FDA Milestones Drive Buy Rating

Maxim Group analyst Jason McCarthy maintained a Buy rating on OS Therapies Incorporated yesterday and set a price target of $6.00.

Jason McCarthy has given his Buy rating due to a combination of factors related to OS Therapies Incorporated’s promising developments. The company is making significant progress with its OST-HER2 program, which targets recurrent osteosarcoma. Recent positive data from their Phase 2b trial, including improved event-free survival and overall survival rates compared to historical controls, highlight the potential efficacy of their treatment. The upcoming End-of-Phase 2 meeting with the FDA and the possibility of a Biologics License Application filing later this year are seen as potential catalysts for the stock.
OST-HER2’s unique approach using a genetically-engineered Listeria monocytogenes strain to stimulate immune responses against HER2-expressing cancer cells has garnered FDA Orphan, Fast Track, and Rare Pediatric Disease designations. These designations not only underscore the treatment’s potential but also provide opportunities for accelerated approval and a priority review voucher, which could significantly enhance the company’s financial position. The analyst’s valuation model, which accounts for commercialization prospects and potential revenue adjustments, supports a 12-month price target of $6.00, reinforcing the Buy recommendation.